Research programme: brain cancer therapies - D-PharmAlternative Names: DP-242; DP-243
Latest Information Update: 08 Nov 2006
At a glance
- Originator D-Pharm
- Mechanism of Action Cell membrane permeability enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Brain cancer
Most Recent Events
- 27 Sep 2006 Discontinued - Preclinical for Brain cancer in Israel (unspecified route)
- 29 Oct 2001 Preclinical development for Brain cancer in Israel (Unknown route)